- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01547169
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days (SNIFF-LONG 21)
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
It is well-known that insulin, a hormone that is naturally secreted by the pancreas, plays an important physiological role by regulating blood sugar levels in the body. The investigators now know that insulin plays many important roles in the brain as well. Insulin seems to be especially active in the part of the brain that corresponds to learning and memory. Studies have shown that when people have insufficient insulin in the brain (which, for example, is the case with Type-II diabetes), they are increasingly at risk to develop memory problems and Alzheimer's disease. In a past study, the investigators administered intravenous insulin to participants and found that it improves their memory. However, that particular method would not be a practical intervention for people with Alzheimer's disease due to the risk of hypoglycemia or exacerbation of insulin resistance. Instead, the investigators use an "intranasal" method of administration, in which the insulin is inserted into a device, and administered intranasally. In this method, the insulin travels directly to the brain, and bypasses the body. Our past studies have also demonstrated that this can be a reliable way to improve memory, and it does not change the body's blood glucose levels.
In our past studies, the investigators have used regular insulin, which lasts about 3-4 hours and creates a similar "spike" in insulin that one would have after eating a meal. However, in normal physiology, the pancreas also releases small and more constant "pulses" of insulin throughout the day and night, establishing a base level of insulin. Accordingly, several longer-lasting types of insulin are now available that last closer to 10-12 hours, mimicking that base level of insulin. The current study uses a long-lasting type of insulin called "insulin detemir," to determine if learning and memory will benefit from a more constant supplement of insulin. the investigators want to determine whether this treatment can benefit people who already have a memory impairment-either they already have a diagnosis of Alzheimer's disease or are diagnosed with mild cognitive impairment, a condition that precedes Alzheimer's disease, and whether a lower or higher dose of insulin detemir is more effective. The investigators will examine cognition, daily function, and different markers of Alzheimer's disease that are in the blood as outcome measures.
The investigators have these specific aims:
- The investigators will test the hypothesis that compared to placebo, three weeks of treatment with intranasal insulin detemir will improve cognition and function in adults with Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI).
- The investigators will determine which of two doses of intranasal insulin detemir produces the greatest improvement in cognition and daily function relative to placebo for adults with AD or MCI.
To examine these hypotheses, the investigators are recruiting approximately 60 participants who have been diagnosed with AD or MCI. They will be randomly selected to take a lower dose of insulin detemir, a higher dose of insulin detemir, or saline (which is an inactive substance and will serve as a placebo). Cognition and the level of daily function will be tested before they begin the study drug, and after 3 weeks of the study drug. The investigators will also measure glucose tolerance and take blood samples to measure markers of AD in the blood.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98108
- VA Puget Sound Health Care System
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 50-89
- Diagnosed with mild cognitive impairment, or mild/moderate AD
Exclusion Criteria:
- Excessively high or low blood pressure, heart rate
- BMI greater than 34
- Pre-existing diabetes not controlled by exercise
- Previous/current use of insulin
- Significant elevations in lipids, liver enzymes
- Menstrual period within the last 12 months
- Significant neurological or medical disorder (other than AD)
- Significant use of nasal decongestants
- Current use of anti-psychotic, anti-convulsive, anxiolytic, glucocorticoids, or sedative medications
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Placebo-vergelijker: Zoutoplossing
|
saline, taken twice per day for a 3 week duration
|
Experimenteel: Low Dose Insulin Detemir (10IU bid)
|
10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
Andere namen:
20IU insulin detemir, administered intranasally twice per day for a 3 week duration
Andere namen:
|
Experimenteel: High Dose Insulin Detemir (20IU bid)
|
10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
Andere namen:
20IU insulin detemir, administered intranasally twice per day for a 3 week duration
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Verbal Memory Composite
Tijdsspanne: Change from Baseline in Verbal Memory at 3 Weeks
|
The composite will consist of the weighted sum of Immediate + Delayed Story Recall and Immediate +Delayed List Recall
|
Change from Baseline in Verbal Memory at 3 Weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Neuropsychological Test of Executive Function 1
Tijdsspanne: Change from Baseline in Executive Functioning at 3 Weeks
|
Computerized Dot Counting Test (test of executive functioning)
|
Change from Baseline in Executive Functioning at 3 Weeks
|
Glucose Tolerance
Tijdsspanne: Change from Baseline in Glucose Tolerance at 3 Weeks
|
Subjects will undergo oral glucose tolerance test (OGTT) to assess glucose tolerance
|
Change from Baseline in Glucose Tolerance at 3 Weeks
|
Functional Ability
Tijdsspanne: Change from Baseline in Functional Ability at 3 Weeks
|
Subjects will have a collateral informant (i.e., spouse or friend) rate the subjects' ability to carry out activities of daily living on the Dementia Severity Rating Scale.
|
Change from Baseline in Functional Ability at 3 Weeks
|
Plasma biomarkers of AD
Tijdsspanne: Change from Baseline in Plasma Biomarkers at 3 Weeks
|
Plasma Abeta (ABeta 38, ABeta 40, and Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject.
|
Change from Baseline in Plasma Biomarkers at 3 Weeks
|
Neuropsychological Test of Executive Functioning 2
Tijdsspanne: Change from Baseline in Executive Functioning at 3 Weeks
|
Computerized Stroop Test
|
Change from Baseline in Executive Functioning at 3 Weeks
|
Neuropsychological Tests of Visual Working Memory
Tijdsspanne: Change from Baseline in Visual Working Memory at 3 Weeks
|
Benton Visual Retention Test Form F&G (a test of visual working memory)
|
Change from Baseline in Visual Working Memory at 3 Weeks
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Suzanne Craft, PhD, VA Puget Sound Health Care System; University of Washington School of Medicine
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Psychische aandoening
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Neurocognitieve stoornissen
- Neurodegeneratieve ziekten
- Dementie
- Tauopathieën
- Cognitieve stoornissen
- Ziekte van Alzheimer
- Cognitieve disfunctie
- Hypoglycemische middelen
- Fysiologische effecten van medicijnen
- Insuline
- Insuline, Globin Zink
- Insuline Detemir
Andere studie-ID-nummers
- 39683-A
- 2P50AG005136-27 (Subsidie/contract van de Amerikaanse NIH)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Milde cognitieve stoornis
-
St. Boniface HospitalPizzey Ingredients; Canadian Agricultural PartnershipActief, niet wervendGeheugen; Verstoring, mildCanada
-
Charite University, Berlin, GermanyGerman Federal Ministry of Education and ResearchOnbekendChronische afasie na een beroerte | Anomie (Word-retrieval Impairment)Duitsland
-
University of California, San FranciscoNational Institute on Aging (NIA)WervingMilde cognitieve stoornis | Cognitieve achteruitgang | Cognitieve achteruitgang | Cognitieve stoornis, mild | Cognitieve tekortkomingen, mildVerenigde Staten
-
DeepsonbioWervingDementie, mild | Cognitieve stoornis MildKorea, republiek van
-
University Hospital, RouenCentre Hospitalier Intercommunal Elbeuf-Louviers / Val de ReuilOnbekendCognitieve stoornis, mild | Dementie, mildFrankrijk
-
Elira, Inc.WervingObesitas, mildVerenigde Staten
-
Irmandade da Misericórdia de Albergaria-a-VelhaVoltooidAngst Depressie (mild of niet aanhoudend)
-
Spectrum Health - LakelandIngetrokkenHersenschudding, mild | Traumatisch hersenletsel, mildVerenigde Staten
-
1st SurgiConceptEVAMEDWerving
-
Logan College of ChiropracticVoltooidAngst, Mild tot MatigVerenigde Staten
Klinische onderzoeken op Placebo Comparator
-
Merck Sharp & Dohme LLCIngetrokken
-
Merck Sharp & Dohme LLCBeëindigd
-
Esther MeijerOnbekendPolycysteuze nier, autosomaal dominant | Autosomaal dominante polycysteuze nier | ADPKDNederland
-
Merck Sharp & Dohme LLCBeëindigd
-
Chong Kun Dang PharmaceuticalVoltooidLuchtweginfectieKorea, republiek van
-
Yooyoung Pharmaceutical Co., Ltd.IngetrokkenArtrose, knieKorea, republiek van
-
Jiangsu HengRui Medicine Co., Ltd.OnbekendReumatoïde artritisChina
-
Autifony Therapeutics LimitedUniversity of NottinghamVoltooidTinnitus, subjectiefVerenigd Koninkrijk
-
Merck Sharp & Dohme LLCVoltooidDiabetes mellitus type 2
-
Jiangsu HengRui Medicine Co., Ltd.Onbekend